References
  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: 359–86.
  2. National Cancer Center Cancer Control Information in Japan. https://ganjoho.jp/reg_stat/statistics/stat/cancer/17_cervix_uteri.html
  3. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet 2013; 382: 889–99.
  4. Small W Jr, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR, Viswanathan AN, Gaffney DK. Cervical cancer: A global health crisis. Cancer 2017; 123: 2404–12.
  5. Sakamoto J, Kamiura S, Okayama K, Okodo M, Shibata T, Osaka Y, Fujita S, Takata E, Takagi H, Takakura M, Sasagawa T. Single type infection of human papillomavirus as a cause for high-grade cervical intraepithelial neoplasia and invasive cancer in Japan. Papillomavirus Res 2018; 6: 46–51.
  6. Onuki M, Yamamoto K, Yahata H, Kanao H, Yokota H, Kato H, Shimamoto K, Takehara K, Kamiura S, Tsuda N, Takei Y, Shigeta S, Matsumura N, Yoshida H, Motohara T, Watari H, Nakamura K, Ueda A, Tasaka N, Ishikawa M, Hirashima Y, Kudaka W, Taguchi A, Iwata T, Takahashi F, Kukimoto I, Yoshikawa H, Yaegashi N, Matsumoto K; MINT Study Group. Human papillomavirus vaccine effectiveness by age at first vaccination among Japanese women. Cancer Sci 2022; 113: 1428–34.
  7. WHO. A cervical cancer-free future: First-ever global commitment to eliminate a cancer. 17 November 2020
  8. Palmer T, Wallace L, Pollock KG, Cuschieri K, Robertson C, Kavanagh K, Cruickshank M. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: Retrospective population study. BMJ 2019; 365: l1161. https://doi.org/10.1136/bmj.l1161
  9. Patel C, Brotherton JM, Pillsbury A, Jayasinghe S, Donovan B, Macartney K, Marshall H. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: What additional disease burden will a nonavalent vaccine prevent? Euro Surveill 2018; 23: pii=1700737. https://doi.org/10.2807/15607917
  10. Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F, Sundström K, Dillner J, Sparén P. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med 2020; 383: 1340–8. https://doi.org/10.1056/NEJMoa1917338
  11. Falcaro M, Castañon A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J, Elliss-Brookes L, Sasieni P. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: A register-based observational study. Lancet 2021; 398: 2084–92.https://doi.org/10.1016/S0140-6736(21)02178-4
  12. Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JM, Cummings T, Donovan B, Fairley CK, Flagg EW, Johnson AM, Kahn JA, Kavanagh K, Kjaer SK, Kliewer EV, Lemieux-Mellouki P, Markowitz L, Mboup A, Mesher D, Niccolai L, Oliphant J, Pollock KG, Soldan K, Sonnenberg P, Tabrizi SN, Tanton C, Brisson M. Population-level impact and herd effects following human papillomavirus vaccination programs: A systematic review and meta-analysis. Lancet Infect Dis 2015; 15: 565–80. https://doi.org/10.1016/S1473-3099(14)71073-4
  13. Donken R, King AJ, Bogaards JA, Woestenberg PJ, Meijer CJLM, de Melker HE. High effectiveness of the bivalent human papillomavirus (HPV) vaccine against incident and persistent HPV infections up to 6 years after vaccination in young Dutch women. J Infect Dis 2018; 217: 1579–89. https://doi.org/10.1093/infdis/jiy067
  14. Gargano JW, McClung N, Lewis RM, Park IU, Whitney E, Castilho JL, Pemmaraju M, Niccolai LM, Brackney M, DeBess E, Ehlers S, Bennett NM, Scahill M, Cleveland AA, Querec TD, Unger ER, Markowitz LE; HPV-IMPACT Working Group. HPV type-specific trends in cervical precancers in the United States, 2008 to 2016. Int J Cancer 2023; 152: 137–50. https://doi.org/10.1002/ijc.34231
  15. Covert C, Ding L, Brown D, Franco EL, Bernstein DI, Kahn JA. Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction. Hum Vaccin Immunother 2019; 15: 1962–9. https://doi.org/10.1080/21645515.2018.1564438
  16. Saccucci M, Franco EL, Ding L, Bernstein DI, Brown D, Kahn JA. Non-vaccine-type human papillomavirus prevalence after vaccine introduction: No evidence for type replacement but evidence for cross-protection. Sex Transm Dis 2018; 45: 260–5. https://doi.org/10.1097/OLQ.0000000000000731
  17. Simms KT, Hanley SJB, Smith MA, Keane A, Canfell K. Impact of HPV vaccine hesitancy on cervical cancer in Japan: A modelling study. Lancet Public Health 2020; 5: e223–34. https://doi.org/10.1016/S2468 2667(20)30010-4
  18. Information of HPV-vaccine program from April 2022; Ministry of Health, Labour and Welfare, Japan. https://www.mhlw.go.jp/content/10906000/000911549.pdf
  19. Karube A, Saito F, Nakamura E, Shitara A, Ono N, Konno M, Tamura D, Nagao D. Reduction in HPV 16/18 prevalence among young women following HPV vaccine introduction in a highly vaccinated district, Japan, 2008-2017. J Rural Med 2019; 14: 48–57. https://doi.org/10.2185/jrm.2986
  20. Ikeda S, Ueda Y, Hara M, Yagi A, Kitamura T, Kitamura Y, Konishi H, Kakizoe T, Sekine M, Enomoto T, Sobue T. Human papillomavirus vaccine to prevent cervical intraepithelial neoplasia in Japan: A nationwide case-control study. Cancer Sci 2021; 112: 839–46. https://doi.org/10.1111/cas.14682
  21. Kudo R, Yamaguchi M, Sekine M, Adachi S, Ueda Y, Miyagi E, Hara M, Hanley SJB, Enomoto T. Bivalent human papillomavirus vaccine effectiveness in a Japanese population: High vaccine-type-specific effectiveness and evidence of cross-protection. J Infect Dis 2019; 219: 382–90. https://doi.org/10.1093/infdis/jiy516
  22. Matsumoto K, Yaegashi N, Iwata T, Yamamoto K, Aoki Y, Okadome M, Ushijima K, Kamiura S, Takehara K, Horie K, Tasaka N, Sonoda K, Takei Y, Aoki Y, Konnai K. Reduction in HPV16/18 prevalence among young women with high-grade cervical lesions following the Japanese HPV vaccination program. Cancer Sci 2019; 110: 3811–20. https://doi.org/10.1111/cas.14212
  23. Sasagawa T, Maehama T, Ideta K, Irie T; Fujiko Itoh J-HERS Study Group. Population-based study for human papillomavirus (HPV) infection in young women in Japan: A multicenter study by the Japanese human papillomavirus disease education research survey group (J-HERS). J Med Virol 2016; 88: 324–35.
The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see:http://www.textcheck.com/certificate/1v9Kxo